Tagged with ERS

China Han Yahui from Chinese folic acid specialist Scrianen outlines her company’s role in keeping mothers and newborns healthy in China, Scrianen’s approach to international partnerships, and the next horizons in it internationalisation strategy.   We need partners who understand that our mission is more than a business What is the…

Japan Writing in DIA’s Global Forum magazine for April 2024 on behalf of DIA Japan’s Open Innovation Community Fumitaka Noji, Takeshi Kono, and Makoto Nagaoka look at how the gap between Japan’s academia and pharma companies can best be bridged to fully reap the benefits of innovation.   Although open innovation in drug…

China Prof. Song Ruilin outlines the Chinese (bio)pharmaceutical industry’s progress across the three key pillars of innovation, industrialization, and internationalization in recent years. While a downturn in the global economy and a capital freeze in the biotech sector present significant challenges, Song is optimistic about his sector’s prospects, with increased international…

LatAm A roundup of some of the latest stories coming out of Latin American pharma and healthcare, including Merck’s new distribution centre in Brazil; the region’s record dengue surge; Roemmers Laboratory’s acquisition of 30% of Argentina’s Tuteur, and Urufarma’s new manufacturing facility in Uruguay.   Merck to open new distribution centre…

China Amid geopolitical tensions and a drop in foreign investments, China continues to encourage international companies to increase their Chinese footprint. At this week’s China Development Forum (CDF), CEOs from Pfizer, AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Novartis, and Takeda made it clear that Big Pharma’s interest in the country has…

India Regular contributor Brendan Shaw gives his informed take on how best international stakeholders can engage with India’s attempts to transform into a global pharma innovation powerhouse,   Our greatest ability as humans is not to change the world, but to change ourselves Mahatma Gandhi The secret to success in India…

USA The Pharmaceutical Research and Manufacturers of America (PhRMA) has had a board reshake, naming Gilead Sciences Chairman and CEO Daniel O’Day as its new chair. The reorganisation comes after the industry group’s failed efforts to block the Inflation Reduction Act (IRA) and the departure of several high-profile members.   Gilead…

India Sampada Gosavi explains how she has led a transformation of Astellas’ operations in India to launch innovative products in oncology and women’s health, coupled with a commitment to building internal capabilities. With a ‘hypergrowth phase’ anticipated, Astellas will nevertheless need to continue to navigate India’s regulatory environment and engage in…

India Dr Basant Garg explains the role and impact of the National Health Authority (NHA) in India, including its pivotal role in executing the Ayushman Bharat universal health coverage initiative. Dr Garg touches on the scale and scope of this enormous undertaking, and some of the implementation challenges of ensuring access…

Portugal Boehringer Ingelheim has a 60-year history in Portugal and, despite challenges in terms of market access and reimbursement delays, remains fully committed to providing innovative healthcare solutions in the country. General Manager Sandra Marques outlines how the firm has established itself as a major player in Portugal’s prescription retail market,…

Portugal Marco Dietrich highlights some of the key challenges in Portugal’s healthcare system, Bayer Portugal’s continuing focus on introducing new products – particularly in diabetes, where Portugal has the highest prevalence in Europe –, and how he has led the strategic transformation of the affiliate focusing on agility and cost-effectiveness.  …

Portugal Ana Fereira highlights how the twin factors of people and time have shaped her leadership approach, how she is navigating the challenging generic medicines landscape in Portugal, and why STADA has chosen to put a strategic focus on biosimilars and sustainability.   I see STADA becoming one of the top…